Compare Stocks → Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ASLNNASDAQ:ATXINASDAQ:KZIANASDAQ:SIOXNASDAQ:ZSAN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.49$0.61$0.39▼$4.69$8.03M1.45876,959 shs152,904 shsATXIAvenue Therapeutics$0.14$0.15$0.11▼$1.28$5.98M-0.244.65 million shs810,701 shsKZIAKazia Therapeutics$0.34+17.1%$0.29$0.19▼$1.68$5.61M2.12778,873 shs322,614 shsSIOXSio Gene Therapies$0.48+1.7%$0.46$0.25▼$0.50N/A1.14N/A40,400 shsZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals-2.69%-13.74%-24.35%-6.33%-86.45%ATXIAvenue Therapeutics+5.28%-10.42%-16.44%-8.10%-88.56%KZIAKazia Therapeutics-5.21%-36.74%+29.97%-15.41%-78.44%SIOXSio Gene Therapies0.00%0.00%0.00%+22.75%+19.17%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…>>Click here to find out what it is.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN Pharmaceuticals2.6118 of 5 stars3.55.00.00.02.30.80.6ATXIAvenue TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals3.00Buy$11.332,208.21% UpsideATXIAvenue Therapeutics3.00BuyN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest ASLN, ZSAN, SIOX, ATXI, and KZIA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $9.003/13/2024ASLNASLAN PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$15.00 ➝ $10.00(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.67N/AN/A$0.60 per share0.82ATXIAvenue TherapeuticsN/AN/AN/AN/A$0.03 per shareN/AKZIAKazia Therapeutics$20K280.31N/AN/A$0.50 per share0.69SIOXSio Gene TherapiesN/AN/AN/AN/AN/AN/AZSANZosano Pharma$790K0.00N/AN/A$9.74 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$2.74N/A∞N/AN/A-862.59%-82.83%4/26/2024 (Estimated)ATXIAvenue Therapeutics-$10.38M-$1.27N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)KZIAKazia Therapeutics-$13.78MN/A0.00N/AN/AN/AN/AN/AN/ASIOXSio Gene Therapies-$71.89MN/A0.00∞N/AN/AN/AN/AN/AZSANZosano Pharma-$29.92M-$14.50N/A∞N/A-8,375.11%-177.06%-119.14%N/ALatest ASLN, ZSAN, SIOX, ATXI, and KZIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023ATXIAvenue TherapeuticsN/A$0.56+$0.56$0.56N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/AKZIAKazia TherapeuticsN/AN/AN/AN/AN/ASIOXSio Gene TherapiesN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A2.112.11ATXIAvenue TherapeuticsN/A1.551.55KZIAKazia TherapeuticsN/A0.71N/ASIOXSio Gene TherapiesN/AN/AN/AZSANZosano PharmaN/A1.611.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%ATXIAvenue Therapeutics17.34%KZIAKazia Therapeutics30.89%SIOXSio Gene TherapiesN/AZSANZosano PharmaN/AInsider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%ATXIAvenue Therapeutics1.80%KZIAKazia Therapeutics1.00%SIOXSio Gene Therapies3.40%ZSANZosano Pharma2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals3416.35 million15.58 millionOptionableATXIAvenue Therapeutics344.26 million43.46 millionNot OptionableKZIAKazia Therapeutics2,02116.34 million16.18 millionOptionableSIOXSio Gene Therapies12N/AN/ANo DataZSANZosano Pharma404.90 million4.78 millionNot OptionableASLN, ZSAN, SIOX, ATXI, and KZIA HeadlinesSourceHeadlineHOOK HOOKIPA Pharma Inc.seekingalpha.com - April 12 at 10:11 PMNachrichten - Weitere Nachrichtenwallstreet-online.de - January 9 at 2:39 PMLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planpbs.org - December 6 at 7:44 AMDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich abn-tv.de - August 22 at 3:36 PMEast Bay Business Newsbizjournals.com - May 18 at 9:49 PMMankind Pharma IPO opens on April 25, listing scheduled for May 9moneycontrol.com - April 27 at 4:20 PMAstellas Pharmaforbes.com - April 6 at 12:00 PMGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundationfinance.yahoo.com - February 5 at 12:11 PMFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orderswashingtonexaminer.com - January 23 at 3:25 PMZosano Pharma Corporation (ZSANQ)ca.finance.yahoo.com - November 5 at 6:33 PMNow bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lillyendpts.com - October 13 at 11:22 AMBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giantsmsn.com - October 12 at 2:32 PMBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claimsmarketwatch.com - August 28 at 7:45 PMEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionbizjournals.com - August 27 at 4:10 PMZosano Pharma Corp (ZSANQ)investing.com - August 25 at 12:28 AMEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1Mbizjournals.com - July 26 at 8:27 PMA Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.bizjournals.com - July 26 at 8:27 PMZosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8dbtnews.com - June 3 at 11:27 AMZosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSANmarketwatch.com - June 2 at 3:26 PMWhy Zosano Pharma Shares Are Getting Hammered Todaymsn.com - June 2 at 3:26 PMZosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%seekingalpha.com - June 2 at 10:26 AMCash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSANmarketwatch.com - June 2 at 10:26 AMEast Bay migraine patch developer files for bankruptcybizjournals.com - June 2 at 10:26 AMZosano Pharma Files Voluntary Petition for Relief Under Chapter 11finance.yahoo.com - June 2 at 10:26 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsASLAN PharmaceuticalsNASDAQ:ASLNASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.Avenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.Kazia TherapeuticsNASDAQ:KZIAKazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.Sio Gene TherapiesNASDAQ:SIOXSio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.Zosano PharmaNASDAQ:ZSANZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.